iRhythm Holdings, Inc.
- IRTC ยท Nasdaq
- Surgical & Medical Instruments & Apparatus
- San Francisco, CA
- 2,400 employees
- CIK 0001388658
Updated from SEC filings through
Top things to know
Executives
-
Quentin S. Blackford President and CEO 4, 2026-08-11 -
Daniel G. Wilson Chief Financial Officer 4, 2026-09-03 - Brice Bobzien former Chief Financial Officer 10-K, 2026-02-19
-
Chad Patterson CHIEF COMM & PRODUCT OFFICER 4, 2026-08-11 -
Sumi Shrishrimal EVP, Chief Risk Officer 4, 2026-08-11 - Minang Turakhia CHIEF MED/SCI OFCR EVP ADVTECH 4, 2026-08-11
What leadership is saying
“Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. We also continued to take meaningful steps forward with significant margin expansion, and consistent execution against our strategic priorities”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
iRhythm Holdings, Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in San Francisco, CA. It trades as IRTC on Nasdaq. Revenue was $747M in the fiscal year ending December 31, 2025, +26.2% from the year before. It reported about 2,400 employees. Quentin S. Blackford is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $747M 10-K, 2026-02-19 | $592M 10-K, 2026-02-19 | $493M 10-K, 2026-02-19 | $411M 10-K, 2025-02-20 | $323M 10-K, 2024-02-22 |
| Operating income | -$57.4M 10-K, 2026-02-19 | -$116M 10-K, 2026-02-19 | -$125M 10-K, 2026-02-19 | -$114M 10-K, 2025-02-20 | -$99.9M 10-K, 2024-02-22 |
| SG&A | $493M 10-K, 2026-02-19 | $419M 10-K, 2026-02-19 | $386M 10-K, 2026-02-19 | $322M 10-K, 2025-02-20 | $275M 10-K, 2024-02-22 |
| Net income | -$44.6M 10-K, 2026-02-19 | -$113M 10-K, 2026-02-19 | -$123M 10-K, 2026-02-19 | -$116M 10-K, 2025-02-20 | -$101M 10-K, 2024-02-22 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Quentin S. Blackford | President and CEO | 4, 2026-08-11 |
| Daniel G. Wilson | Chief Financial Officer | 4, 2026-09-03 |
| Daniel Wilson Public Healthcare CFO | Value-Creation & Scale Leader | Board Advisor & Operator-Investor | MedTech, Digital Health, HealthTech | Named in proxy bio: Chief Financial Officer | DEF 14A, 2026-04-17 |
| Brice Bobzien Chief Financial Officer at iRhythm | former Chief Financial Officer | 10-K, 2026-02-19 |
| Chad Patterson EVP, Chief Commercial and Product Officer at iRhythm | CHIEF COMM & PRODUCT OFFICER | 4, 2026-08-11 |
| Sumi Shrishrimal Chief Risk Officer and Executive Vice President, iRhythm | EVP, Chief Risk Officer | 4, 2026-08-11 |
| Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | 4, 2026-08-11 |
| Julianne Rodda | EVP, CHIEF PEOPLE OFFICER | 4, 2026-08-04 |
| Marc Wade Rosenbaum | Chief Accounting Officer | 4, 2026-06-03 |
 Brian Lee Lawrence | Chief Technology Officer | 4, 2026-05-05 |
| Brian Lawrence Innovation and Technology Leader, Entrepreneur, Innovator, Product Developer, and Business Leader | Named in proxy bio: EVP, Chief Technology Officer | DEF 14A, 2026-04-17 |
 Julie Rodda EVP, Chief People & Capability Officer | Named in proxy bio: EVP, Chief People & Capability Officer | DEF 14A, 2026-04-17 |
 Patrick Murphy Chief Business Officer and Chief Legal Officer | Named in proxy bio: Chief Business Officer and Chief Legal Officer | DEF 14A, 2026-04-17 |
| Minang (Mintu) Turakhia, M.D., M.S. | Named in proxy bio: Chief Medical Officer, Chief Scientific Officer, and EVP, Advanced Technologies | DEF 14A, 2026-04-17 |
| Marc Rosenbaum Senior Vice President, Finance / Accounting and Chief Accounting Officer at iRhythm Technologies, Inc. | SVP, Chief Accounting Officer | 10-K, 2026-02-19 |
 Mintu Turakhia | Chief Medical Officer, Chief Scientific Officer, and Executive Vice President of Advanced Technologies | 10-K, 2026-02-19 |
What iRhythm Holdings, Inc. does
iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 33.6 million (as of October 29, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $4.9B (as of June 30, 2025) | 10-K, February 19, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting December 31, 2025 (filed April 17, 2026) | DEF 14A, April 17, 2026 |
| Auditor | PricewaterhouseCoopers LLP (San Jose, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 2, 2026 | Daniel G. Wilson Chief Financial Officer | Sale | 773 | $94K | Form 4, September 3, 2026 |
| August 10, 2026 | Minang Turakhia CHIEF MED/SCI OFCR EVP ADVTECH | Sale | 7,093 | $884K | Form 4, August 11, 2026 |
| August 10, 2026 | Sumi Shrishrimal EVP, Chief Risk Officer | Sale | 5,372 | $670K | Form 4, August 11, 2026 |
| August 10, 2026 | Chad Patterson CHIEF COMM & PRODUCT OFFICER | Sale | 7,093 | $884K | Form 4, August 11, 2026 |
| August 10, 2026 | Patrick Michael Murphy CBO and CLO | Sale | 7,093 | $884K | Form 4, August 11, 2026 |
| August 10, 2026 | Quentin S. Blackford President and CEO | Sale | 26,859 | $3.3M | Form 4, August 11, 2026 |
| August 3, 2026 | Julianne Rodda EVP, CHIEF PEOPLE OFFICER | Sale | 2,112 | $258K | Form 4, August 4, 2026 |
| August 3, 2026 | Mervin Smith EVP Strategic Business Ops | Sale | 617 | $75K | Form 4, August 4, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-05
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-22
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-06
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-08-06
- Item 1.01 Entry into a material definitive agreement
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-15
- Item 1.05 Material cybersecurity incident
- 8-K filed 2026-06-05
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-28
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about iRhythm Holdings, Inc.
- What does iRhythm Holdings, Inc. do?
- In its own words, from Item 1 of its 10-K: "iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology."
- What is iRhythm Holdings, Inc.'s revenue?
- $747M for the fiscal year ending December 31, 2025, from its 10-K filed February 19, 2026.
- Is iRhythm Holdings, Inc. profitable?
- iRhythm Holdings, Inc. reported net income of -$44.6M for the fiscal year ending December 31, 2025.
- How many employees does iRhythm Holdings, Inc. have?
- About 2,400 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of iRhythm Holdings, Inc.?
- Quentin S. Blackford, President and CEO, as named in a 4 filed August 11, 2026.
- Who is the CFO of iRhythm Holdings, Inc.?
- Daniel G. Wilson, Chief Financial Officer, as named in a 4 filed September 3, 2026.
- Where is iRhythm Holdings, Inc. headquartered?
- San Francisco, CA.
- What is iRhythm Holdings, Inc.'s stock ticker?
- IRTC on Nasdaq.
- What industry is iRhythm Holdings, Inc. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is iRhythm Holdings, Inc.'s website?
- irhythmtech.com.
- When does iRhythm Holdings, Inc. report earnings next?
- November 12, 2026. Source: estimate_8k_pattern.
- Is iRhythm Holdings, Inc. a public company?
- Yes. iRhythm Holdings, Inc. files with the SEC under CIK 0001388658 and trades as IRTC.
- Who audits iRhythm Holdings, Inc.?
- PricewaterhouseCoopers LLP, San Jose, California, as named in its latest annual report (10-K).
- How many shares of iRhythm Holdings, Inc. are outstanding?
- 33.6 million shares as of October 29, 2026, from its 10-Q filed November 5, 2026.
- What is iRhythm Holdings, Inc.'s public float?
- $4.9B as of June 30, 2025, as reported on the cover of its 10-K filed February 19, 2026.
- How many business segments does iRhythm Holdings, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is iRhythm Holdings, Inc.'s annual shareholder meeting?
- December 31, 2025, per its proxy statement (DEF 14A) filed April 17, 2026.
- Have iRhythm Holdings, Inc. insiders traded stock recently?
- Since July 2, 2025, officers and directors reported 50 open-market sales worth about $37.6M and 1 purchase worth about $57K on Forms 4 and 5. The most recent: Daniel G. Wilson (Chief Financial Officer) sold 773 shares on September 2, 2026.